View ValuationSvas Biosana 향후 성장Future 기준 점검 1/6Svas Biosana (는) 각각 연간 6.6% 및 2.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 4.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.6% 로 예상됩니다.핵심 정보6.6%이익 성장률4.52%EPS 성장률Medical Equipment 이익 성장14.0%매출 성장률2.8%향후 자기자본이익률9.60%애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.모든 업데이트 보기Recent updatesUpcoming Dividend • May 25Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (2.3%).Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.공시 • May 06Svas Biosana S.p.A., Annual General Meeting, May 20, 2026Svas Biosana S.p.A., Annual General Meeting, May 20, 2026, at 16:00 W. Europe Standard Time.Declared Dividend • Apr 19Dividend reduced to €0.20Dividend of €0.20 is 20% lower than last year. Ex-date: 1st June 2026 Payment date: 3rd June 2026 Dividend yield will be 2.2%, which is higher than the industry average of 1.7%. Sustainability & Growth The dividend has decreased by an average of 8.7% per year over the past 2 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 17Svas Biosana S.p.A. announces Annual dividend, payable on June 03, 2026Svas Biosana S.p.A. announced Annual dividend of EUR 0.2000 per share payable on June 03, 2026, ex-date on June 01, 2026 and record date on June 02, 2026.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.7m market cap, or US$53.9m).New Risk • Jan 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (5.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€43.4m market cap, or US$50.5m).Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.3% over the past three years.분석 기사 • Oct 31Is Now An Opportune Moment To Examine Svas Biosana S.p.A. (BIT:SVS)?Svas Biosana S.p.A. ( BIT:SVS ), is not the largest company out there, but it led the BIT gainers with a relatively...공시 • Jun 26Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million.Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million on June 26, 2025. The consideration of €0.9 million, to be paid over three years, in addition to an earn-out - a variable component linked to the achievement of specific economic results (EBITDA) in the next four years. SVAS has also committed to supporting the growth of MEHOS through a loan of 1 million, to be disbursed within three years. The transaction is expected to close by July 2025. The acquisition and the related financing commitment will be entirely supported by own funds. For the period ending December 31, 2024, Mehos S.R.L. reported total revenue of €5.6 million and EBITDA of €7000.Upcoming Dividend • Jun 02Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 11 June 2025. Payout ratio is a comfortable 23% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Italian dividend payers (5.4%). Higher than average of industry peers (1.7%).분석 기사 • May 16Svas Biosana's (BIT:SVS) Profits May Not Reveal Underlying IssuesThe recent earnings posted by Svas Biosana S.p.A. ( BIT:SVS ) were solid, but the stock didn't move as much as we...공시 • May 07Svas Biosana S.p.A., Annual General Meeting, May 20, 2025Svas Biosana S.p.A., Annual General Meeting, May 20, 2025, at 16:00 W. Europe Standard Time.Declared Dividend • Apr 20Dividend reduced to €0.25Dividend of €0.25 is 17% lower than last year. Ex-date: 9th June 2025 Payment date: 11th June 2025 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.공시 • Apr 19Svas Biosana S.p.A. announces Annual dividend, payable on June 11, 2025Svas Biosana S.p.A. announced Annual dividend of EUR 0.2500 per share payable on June 11, 2025, ex-date on June 09, 2025 and record date on June 10, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€39.1m market cap, or US$44.3m).Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.Reported Earnings • Oct 01First half 2024 earnings releasedFirst half 2024 results: Revenue: €59.0m (up 3.8% from 1H 2023). Net income: €2.62m (up 14% from 1H 2023). Profit margin: 4.4% (up from 4.0% in 1H 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Italy.분석 기사 • May 10Svas Biosana's (BIT:SVS) Earnings Are Weaker Than They SeemSvas Biosana S.p.A. ( BIT:SVS ) announced strong profits, but the stock was stagnant. Our analysis suggests that this...New Risk • May 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€43.5m market cap, or US$46.9m).Reported Earnings • May 02Full year 2023 earnings releasedFull year 2023 results: Revenue: €121.6m (up 22% from FY 2022). Net income: €5.12m (up 44% from FY 2022). Profit margin: 4.2% (up from 3.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€44.0m market cap, or US$46.8m).분석 기사 • Dec 09The Returns At Svas Biosana (BIT:SVS) Aren't GrowingIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €97.2m (up 19% from FY 2021). Net income: €3.57m (up 13% from FY 2021). Profit margin: 3.7% (down from 3.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe.공시 • Feb 01+ 2 more updatesSvas Biosana S.p.A. to Report First Half, 2023 Results on Sep 26, 2023Svas Biosana S.p.A. announced that they will report first half, 2023 results on Sep 26, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Oct 06We Think You Should Be Aware Of Some Concerning Factors In Svas Biosana's (BIT:SVS) EarningsFollowing the solid earnings report from Svas Biosana S.p.A. ( BIT:SVS ), the market responded by bidding up the stock...Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €44.7m (up 129% from 1H 2021). Net income: €1.72m (up 74% from 1H 2021). Profit margin: 3.8% (down from 5.1% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Europe.공시 • Jun 24Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o.Svas Biosana S.p.A. (BIT:SVS) agreed to acquire 75% stake in the Bormia, trgovina in storitve, d.o.o. for EUR 4.8 million on May 17, 2022. With this transaction, Svas Biosana becomes a leader in the supply of medical devices in the Balkans area. The transaction involves the sale of a total of three shares in Bormia, representing 75% of the relative share capital, by the shareholders Maja Vecerina, Igor Bogatec and Boris Cotic, for a total consideration final amount of EUR 4.8 million, to be paid in full at closing. Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o. on June 23, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Feb 15+ 2 more updatesSvas Biosana S.p.A. to Report Fiscal Year 2021 Results on Apr 14, 2022Svas Biosana S.p.A. announced that they will report fiscal year 2021 results on Apr 14, 2022공시 • Dec 11SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million.SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: €12.5이익 및 매출 성장 예측BIT:SVS - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281548710112/31/2027149838112/31/20261457610112/31/20251427-66N/A9/30/20251387-63N/A6/30/20251357-7-1N/A3/31/20251296-42N/A12/31/20241226-15N/A9/30/2024123606N/A6/30/2024124506N/A3/31/20241235-15N/A12/31/20231225-24N/A9/30/2023117527N/A6/30/2023112459N/A3/31/2023106427N/A12/31/2022100405N/A9/30/2022943-60N/A6/30/2022883-13-5N/A3/31/2022853-8-1N/A12/31/2021823-33N/A9/30/202180326N/A6/30/202179379N/A3/31/2021783810N/A12/31/20207731011N/A12/31/2019100407N/A12/31/2018943N/A9N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SVS 의 연간 예상 수익 증가율(6.6%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: SVS 의 연간 수익(6.6%)이 Italian 시장(11.3%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: SVS 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SVS 의 수익(연간 2.8%)이 Italian 시장(연간 5.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SVS 의 수익(연간 2.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SVS의 자본 수익률은 3년 후 9.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 20:13종가2026/06/10 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Svas Biosana S.p.A.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Simone MieliTPICAP MidcapMathias PaladinoTPICAP Midcap
Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.
Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.
Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.
Upcoming Dividend • May 25Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (2.3%).
Major Estimate Revision • May 13Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week.
공시 • May 06Svas Biosana S.p.A., Annual General Meeting, May 20, 2026Svas Biosana S.p.A., Annual General Meeting, May 20, 2026, at 16:00 W. Europe Standard Time.
Declared Dividend • Apr 19Dividend reduced to €0.20Dividend of €0.20 is 20% lower than last year. Ex-date: 1st June 2026 Payment date: 3rd June 2026 Dividend yield will be 2.2%, which is higher than the industry average of 1.7%. Sustainability & Growth The dividend has decreased by an average of 8.7% per year over the past 2 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 17Svas Biosana S.p.A. announces Annual dividend, payable on June 03, 2026Svas Biosana S.p.A. announced Annual dividend of EUR 0.2000 per share payable on June 03, 2026, ex-date on June 01, 2026 and record date on June 02, 2026.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.7m market cap, or US$53.9m).
New Risk • Jan 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (5.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€43.4m market cap, or US$50.5m).
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.3% over the past three years.
분석 기사 • Oct 31Is Now An Opportune Moment To Examine Svas Biosana S.p.A. (BIT:SVS)?Svas Biosana S.p.A. ( BIT:SVS ), is not the largest company out there, but it led the BIT gainers with a relatively...
공시 • Jun 26Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million.Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million on June 26, 2025. The consideration of €0.9 million, to be paid over three years, in addition to an earn-out - a variable component linked to the achievement of specific economic results (EBITDA) in the next four years. SVAS has also committed to supporting the growth of MEHOS through a loan of 1 million, to be disbursed within three years. The transaction is expected to close by July 2025. The acquisition and the related financing commitment will be entirely supported by own funds. For the period ending December 31, 2024, Mehos S.R.L. reported total revenue of €5.6 million and EBITDA of €7000.
Upcoming Dividend • Jun 02Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 11 June 2025. Payout ratio is a comfortable 23% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Italian dividend payers (5.4%). Higher than average of industry peers (1.7%).
분석 기사 • May 16Svas Biosana's (BIT:SVS) Profits May Not Reveal Underlying IssuesThe recent earnings posted by Svas Biosana S.p.A. ( BIT:SVS ) were solid, but the stock didn't move as much as we...
공시 • May 07Svas Biosana S.p.A., Annual General Meeting, May 20, 2025Svas Biosana S.p.A., Annual General Meeting, May 20, 2025, at 16:00 W. Europe Standard Time.
Declared Dividend • Apr 20Dividend reduced to €0.25Dividend of €0.25 is 17% lower than last year. Ex-date: 9th June 2025 Payment date: 11th June 2025 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.
공시 • Apr 19Svas Biosana S.p.A. announces Annual dividend, payable on June 11, 2025Svas Biosana S.p.A. announced Annual dividend of EUR 0.2500 per share payable on June 11, 2025, ex-date on June 09, 2025 and record date on June 10, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€39.1m market cap, or US$44.3m).
Price Target Changed • Jan 10Price target decreased by 10% to €12.40Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year.
Reported Earnings • Oct 01First half 2024 earnings releasedFirst half 2024 results: Revenue: €59.0m (up 3.8% from 1H 2023). Net income: €2.62m (up 14% from 1H 2023). Profit margin: 4.4% (up from 4.0% in 1H 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Italy.
분석 기사 • May 10Svas Biosana's (BIT:SVS) Earnings Are Weaker Than They SeemSvas Biosana S.p.A. ( BIT:SVS ) announced strong profits, but the stock was stagnant. Our analysis suggests that this...
New Risk • May 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€43.5m market cap, or US$46.9m).
Reported Earnings • May 02Full year 2023 earnings releasedFull year 2023 results: Revenue: €121.6m (up 22% from FY 2022). Net income: €5.12m (up 44% from FY 2022). Profit margin: 4.2% (up from 3.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€44.0m market cap, or US$46.8m).
분석 기사 • Dec 09The Returns At Svas Biosana (BIT:SVS) Aren't GrowingIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Price Target Changed • Aug 07Price target decreased by 16% to €13.80Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year.
Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €97.2m (up 19% from FY 2021). Net income: €3.57m (up 13% from FY 2021). Profit margin: 3.7% (down from 3.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe.
공시 • Feb 01+ 2 more updatesSvas Biosana S.p.A. to Report First Half, 2023 Results on Sep 26, 2023Svas Biosana S.p.A. announced that they will report first half, 2023 results on Sep 26, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Oct 06We Think You Should Be Aware Of Some Concerning Factors In Svas Biosana's (BIT:SVS) EarningsFollowing the solid earnings report from Svas Biosana S.p.A. ( BIT:SVS ), the market responded by bidding up the stock...
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €44.7m (up 129% from 1H 2021). Net income: €1.72m (up 74% from 1H 2021). Profit margin: 3.8% (down from 5.1% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Europe.
공시 • Jun 24Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o.Svas Biosana S.p.A. (BIT:SVS) agreed to acquire 75% stake in the Bormia, trgovina in storitve, d.o.o. for EUR 4.8 million on May 17, 2022. With this transaction, Svas Biosana becomes a leader in the supply of medical devices in the Balkans area. The transaction involves the sale of a total of three shares in Bormia, representing 75% of the relative share capital, by the shareholders Maja Vecerina, Igor Bogatec and Boris Cotic, for a total consideration final amount of EUR 4.8 million, to be paid in full at closing. Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o. on June 23, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Feb 15+ 2 more updatesSvas Biosana S.p.A. to Report Fiscal Year 2021 Results on Apr 14, 2022Svas Biosana S.p.A. announced that they will report fiscal year 2021 results on Apr 14, 2022
공시 • Dec 11SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million.SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: €12.5